Merc AND Co. have developed an experimental COVID pill that could reduce the chances of hospitalisation and death in COVID patients
Marketed by the name Molnupiravir, would create an error in the genetic code of the virus and would be the first oral antiviral medicine foe COVID 19. The global supply of the medicine is still not clear. Merck and their partner Ridgeback Biotherapeutics said that they are aiming to seek and emergency approval from the US government for the same.
The trail for the drug was conducted on 775 patients. It was seen that only 7.3percent of those given Molnupiravir twice daily for 5 days were hospitalised and no one died after 29 days if the treatment .
There are no severe affects of the drugs yet though there would be guidelines issued for the usage of the same.
This drug could be a game changer. Pfizer and the Swiss drug maker Roche Holding are also in the line to develop the antiviral pill for Covid 19.
